July 2019
Volume 60, Issue 9
ARVO Annual Meeting Abstract  |   July 2019
Intraocular pressure reduction profile in patients with refractory glaucoma submitted to micropulse transscleral cyclophotocoagulation
Author Affiliations & Notes
  • Larissa Ibrahim
    Instituto de Olhos Ciências Médicas, Brazil
  • Ariel Chaves
    Instituto de Olhos Ciências Médicas, Brazil
  • Tereza Kanadani
    Instituto de Olhos Ciências Médicas, Brazil
  • Syril Dorairaj
    Mayo Clinic, Florida, United States
  • Tiago Prata
    Hospital Medicina dos Olhos, Osasco, Brazil
  • Fabio Kanadani
    Instituto de Olhos Ciências Médicas, Brazil
  • Footnotes
    Commercial Relationships   Larissa Ibrahim, None; Ariel Chaves, None; Tereza Kanadani, None; Syril Dorairaj, None; Tiago Prata, None; Fabio Kanadani, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 705. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Larissa Ibrahim, Ariel Chaves, Tereza Kanadani, Syril Dorairaj, Tiago Prata, Fabio Kanadani; Intraocular pressure reduction profile in patients with refractory glaucoma submitted to micropulse transscleral cyclophotocoagulation. Invest. Ophthalmol. Vis. Sci. 2019;60(9):705. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To evaluate the results of micropulse transsscleral cyclophotocoagulation diode laser (MP-TSCPC) in a minimum 6-month period in patients with refractory glaucoma.

Methods : This is a retrospective and non-comparative study. Data from patients with refractory glaucoma (at least one unsuccessful filtering procedure) submitted to MP-TSCPC by the same surgeon from 2017 until January 2018, according to a pre-defined protocol of energy and time of application were collected. Intraocular pressure (IOP) and number of antiglaucomatous medications were compared before and after surgery and adverse events were recorded. Finally, the correlation between the initial response to the treatment and the magnitude of final pressure reduction was evaluated.

Results : A total of 34 patients (37 eyes) with a minimum follow-up of 6 months (mean follow-up was 10.52 months) were included. The diagnoses were primary glaucoma (PG, 62%), secondary glaucoma (SG, 14%) and congenital/juvenile glaucoma (CG/J, 24%). The mean age was 46 ± 19.9 years. The mean IOP reduction was 23.3%, from 23.8 ± 6.7 mmHg (8 to 40 mmHg) to 17.8 ± 6.2 mmHg (8 to 30 mmHg) at the last visit (p <0.001). The mean reduction of topical hypotensive medications was 2.8 ± 0.7 (1 to 4) to 1.7 ± 1.1 (0 to 4) (p <0.001) and oral acetazolamide use was 17 (50%) to 8 patients (23.5%) at the last visit. There was a positive correlation between the initial response to treatment (after 1 month) and the magnitude of pressure reduction after 6 months (p = 0.038). The mean IOP reduction in PG patients was 24.4%, 23% in SG and 20.6% in CG/J. The success rate (defined as IOP reduction>25%) at the last visit was 58%, when considered an IOP reduction >20% the success rate increased to 61%. No significant side effects were observed during follow-up although 6 patients required a second MP-TSCPC application between 2 and 6 months after initial treatment.

Conclusions : Our short-term results in refractory glaucoma eyes have shown that MP-TSCPC may be an effective alternative for IOP reduction in about 58% of the cases, and a reduction in topical hypotensive medications may be an advantage. The initial response profile appears to be a predictor of positive outcome at the end of 6 months. Further studies are needed to assess the long-term efficacy and safety profile.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.




This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.